1. Introduction
===============

Nitrogen-containing heterocyclic compounds have a diverse range of biological and pharmacological properties \[[@B1-molecules-19-02637],[@B2-molecules-19-02637],[@B3-molecules-19-02637]\]. Pyridazine and pyridine derivatives are two of the most important heterocycles found in medicinal chemistry as they have an excellent biological activity with a wide range of applications, including antimicrobial \[[@B4-molecules-19-02637],[@B5-molecules-19-02637],[@B6-molecules-19-02637]\], antiinflammatory and analgesic \[[@B7-molecules-19-02637],[@B8-molecules-19-02637],[@B9-molecules-19-02637]\], anti-HIV \[[@B10-molecules-19-02637]\], antiplasmodial \[[@B11-molecules-19-02637]\], antitubercular \[[@B3-molecules-19-02637],[@B12-molecules-19-02637]\], antibacterial \[[@B3-molecules-19-02637],[@B13-molecules-19-02637]\], anticonvulsant \[[@B14-molecules-19-02637],[@B15-molecules-19-02637]\], COX inhibitor \[[@B16-molecules-19-02637]\], antidiabetic \[[@B17-molecules-19-02637]\], antihypertensive \[[@B18-molecules-19-02637],[@B19-molecules-19-02637]\], anticancer effects \[[@B20-molecules-19-02637],[@B21-molecules-19-02637],[@B22-molecules-19-02637],[@B23-molecules-19-02637],[@B24-molecules-19-02637]\], blood platelet aggregation inhibitors \[[@B25-molecules-19-02637]\], antidepressant and anxiolytic \[[@B26-molecules-19-02637],[@B27-molecules-19-02637]\], antioxidant \[[@B28-molecules-19-02637]\], antitumor \[[@B29-molecules-19-02637],[@B30-molecules-19-02637]\] and antifungal activities \[[@B31-molecules-19-02637]\]. For example Isoniazide and Amlodipine are two drugs containing the pyridine motif as anti-tuberculosis and anti-hypertensive respectively ([Figure 1](#molecules-19-02637-f001){ref-type="fig"}). On the basis of the above findings the pyridine and pyridazine moieties are considered privileged structures and, consequently, they have attracted the general and continuing interest of synthetic organic chemists.

![Drugs containing the pyridine motif.](molecules-19-02637-g001){#molecules-19-02637-f001}

2. Results and Discussion
=========================

In earlier investigations we developed methods for the efficient synthesis of a variety of polyfunctional azoles, azines and their fused derivatives \[[@B32-molecules-19-02637],[@B33-molecules-19-02637],[@B34-molecules-19-02637],[@B35-molecules-19-02637],[@B36-molecules-19-02637]\]. Recent efforts in our laboratories have led to the design of new and general strategies for the preparation of 2-amino-5-arylazo-nicotinates and pyridazinones \[[@B37-molecules-19-02637]\] that involve reactions of 3-oxo-2-arylhydrazonopropanals **1** with active methylene compounds, including ethyl cyanoacetate, and malononitrile, depending on the effect of the substituent present in the arylazo moiety. Now it was of interest to explore the scope and limitations and generality of the 3-oxo-2-arylhydrazonopropanals **1** as a precursor for the synthesis of some new polyfunctionally substituted pyridazines and pyridines. In order to establish a general route for the synthesis of pyridazin-3-one derivatives **3** as sole products we conducted the reaction between 3-oxo-2-arylhydrazonopropanals **1** and some active methylene compounds, namely *p*-nitrophenylacetic acid (**2a**), *o*-nitrophenylacetic acid (**2b**) and cyanoacetic acid (**2c**) in acetic anhydride. Under these conditions only the pyridazin-3-one derivatives **3** were formed as sole isolable products in excellent yield. The structure of the pyridazin-3-one derivatives **3** was established based on their spectroscopic analyses and X-ray crystallographic analysis ([Scheme 1](#molecules-19-02637-f005){ref-type="scheme"}, [Figure 2](#molecules-19-02637-f002){ref-type="fig"} and [Figure 3](#molecules-19-02637-f003){ref-type="fig"}).

![Synthesis of pyridazin-3-one derivatives **3a**--**l**.](molecules-19-02637-g005){#molecules-19-02637-f005}

![ORTEP plot of the X-ray crystallographic data determined for **3d** \[[@B38-molecules-19-02637]\].](molecules-19-02637-g002){#molecules-19-02637-f002}

![ORTEP plot of the X-ray crystallographic data determined for **3l** \[[@B39-molecules-19-02637]\].](molecules-19-02637-g003){#molecules-19-02637-f003}

A plausible mechanism for the formation of pyridazin-3-ones **3** ([Scheme 2](#molecules-19-02637-f006){ref-type="scheme"}) involves a condensation reaction between the two substrates **1** and **2** to generates the alkylidene intermediate **A**, which then undergoes cyclization via elimination of another water molecule to afford smoothly the pyridazin-3-ones **3**. As illustrated in this mechanism, only two consecutive eliminations of water molecules in the presence of acetic anhydride as a reaction medium were needed to afford only the pyridazin-3-ones **3** in all cases and the formation of the 5-arylazopyridines not observed, due to the absence of ammonium acetate which furnishes the ammonia that plays an essential rule in the formation of the 5-arylazopyridines as described in previous studies \[[@B37-molecules-19-02637],[@B40-molecules-19-02637]\] and also in the forthcoming examples in this study.

![**A** plausible mechanism for the formation of pyridazin-3-ones **3**.](molecules-19-02637-g006){#molecules-19-02637-f006}

In order to synthesize a new class of enaminone derivatives the 6-acetyl-3-oxopyridazine derivative **3l** was condensed with dimethylformamide dimethylacetal (DMF-DMA) in dioxane to yield the corresponding enaminone **4**, whose ^1^H-NMR spectrum revealed the characteristic two doublet bands for the two olefinic CHs at δ 5.88 and 7.81, respectively, and two signals due to the two methyl groups at δ 2.84 and 3.15, respectively. Moreover MS and HRMS showed its expected M^+^ ion. The foregoing results prompted us to investigate the behaviour of the enaminone **4** towards some *N*-nucleophiles such as heterocyclic amines, as potential precursors of polyfunctionally-substituted fused pyrimidine derivatives for which we expect a broad spectrum of biological activity ([Scheme 3](#molecules-19-02637-f007){ref-type="scheme"}).

![Reactions of the enaminone **4** with heterocyclic amines.](molecules-19-02637-g007){#molecules-19-02637-f007}

Thus the enaminone **4** was reacted with 3-amino-1,2,4-triazole, 3-phenyl-5-aminopyrazole and 2-aminobenzimidazole in refluxing pyridine to afford the corresponding azolo\[1,5-*a*\]pyrimidine derivatives **5**--**7** that incorporate the pyridazin-3-one moiety. A plausible mechanism for the formation of triazolo\[1,5-*a*\]pyrimidine derivatives **5** is taken as a representative example to explain the reaction between the enaminone **4** and heterocyclic amines ([Scheme 4](#molecules-19-02637-f008){ref-type="scheme"}).

![A plausible mechanism for the formation of triazolo\[1,5-*a*\]pyrimidine derivatives **5**.](molecules-19-02637-g008){#molecules-19-02637-f008}

First a Michael-type addition of the exocyclic amino group in the aminotriazole to the α,β-unsaturated moiety in the enaminone **4** yields the corresponding acyclic non-isolable intermediate **B**, which forms the intermediate **C** via elimination of a dimethylamine molecule, and then the intermediate **C** undergoes cyclization through the addition of the NH to CO group to form the intermediate **D**, followed by aromatization via loss of one water molecule to form finally the triazolo\[1,5-*a*\]pyrimidine derivative **5**.

In a recent study \[[@B40-molecules-19-02637]\] we have also demonstrated that 2-amino-6-aryl-5-arylazo-3-benzoylpyridines **10** were formed as the sole isolable products in the reaction between 3-oxo-3-phenylpropionitrile (**9**) and 3-oxo-2-arylhydrazonopropanals **8a**--**b** containing electron poor arylhydrazone groups as substrates, possessing two electron-withdrawing nitro and Cl groups on the aryl ring of this moiety ([Scheme 5](#molecules-19-02637-f009){ref-type="scheme"}).

![Synthesis of 2-aminopyridines **10** \[[@B40-molecules-19-02637]\].](molecules-19-02637-g009){#molecules-19-02637-f009}

It was therefore of interest to explore the scope, limitations and extend the generality of reaction between 3-oxo-2-arylhydrazonopropanals **8a** with miscellaneous active methylene compounds like 3-oxo-3-phenylpropionitrile, hetaroylacetonitriles and cyanoacetamides to afford polyfunctionally substituted 2-aminopyridines and their utility in the synthesis of 1,8-naphthyridine derivatives. Thus we explored reactions between 3-oxo-2-arylhydrazonopropanal **8a** and cyanoacetylindoles **11**,**12** and different cyanoacetamides **13**,**14**. These processes afford products which were shown to be the respective 2-aminopyridine derivatives **16**--**19** and it is believed that these 2-aminopyridines were formed via the intermediacy of **E**--**G**, as illustrated in the mechanistic pathway presented in ([Scheme 6](#molecules-19-02637-f010){ref-type="scheme"}).

![A plausible mechanism for the formation of 2-aminopyridines.](molecules-19-02637-g010){#molecules-19-02637-f010}

In contrast to the observed behaviour of **11**--**14** towards **8a** the thiophene cyanoacetamide **15** behaves differently, affording the pyridazinimine derivatives **20** and not the 2-aminopyridine derivatives **21** or the 2-oxopyridines **22** according to the ^1^H-NMR spectra which showed two signals at δ ≈ 9.80 and 13.3 ppm corresponding to two NH groups, one for the imine NH and the other for the amide NH. Also the ^13^C-NMR spectrum showed a signal at δ ≈ 187.5 corresponding to a true ketone CO and not an amide CO. Till now the factors that make the thiophene cyanoacetamide afford the pyridazine and not pyridine are not clear, but this behaviour may be related to the nature of the thiophene heterocyclic ring and is compatible with an earlier study in which when 3-oxo-2-thiophenehydrazonopropanal reacts with ethyl cyanoacetate, it also affords the pyridazine and not the pyridine system \[[@B41-molecules-19-02637]\]. The structures of these substances were assigned based on their spectroscopic and mass spectrometric properties and X-ray single crystal determination ([Scheme 7](#molecules-19-02637-f011){ref-type="scheme"}, [Figure 4](#molecules-19-02637-f004){ref-type="fig"}).

In order to complete the goal of this study we conducted a reaction between the 2-aminopyridine derivatives **10a**,**b** and cyanoacetic acid in the presence of acetic anhydride to smoothly afford the desired 1,8-naphthyridinecarbonitrile derivatives **24a**,**b** in very good yield. The reaction proceeds most likely via the intermediacy of **23** ([Scheme 8](#molecules-19-02637-f012){ref-type="scheme"}).

![Reaction of arylhydrazonopropanal **8a** with miscellaneous active methylene compounds.](molecules-19-02637-g011){#molecules-19-02637-f011}

![ORTEP plot of the X-ray crystallographic data determined for **18** \[[@B42-molecules-19-02637]\].](molecules-19-02637-g004){#molecules-19-02637-f004}

![Synthesis of 1,8-naphthyridines **24**.](molecules-19-02637-g012){#molecules-19-02637-f012}

3. Experimental
===============

3.1. General
------------

Melting points were recorded and are reported uncorrected. The IR spectra were recorded using KBr pellets on a JASCO FTIR-6300 FT-IR spectrophotometer (Mary's Court, Easton, MD, USA). ^1^H-NMR (400 MHz) or (600 MHz) and ^13^C-NMR (100 MHz) or (150 MHz) spectra were recorded at 25 °C using CDCl~3~ or DMSO-*d~6~* solutions with TMS as an internal standard on a Bruker DPX 400 or 600 super-conducting NMR spectrometer (Rheinstetten, Germany). Chemical shifts are reported in ppm. Low-resolution electron impact mass spectra \[MS (EI)\] and high-resolution electron impact mass spectra \[HRMS (EI)\] were measured using a high resolution GC-MS (DFS) thermo spectrometer at 70.1 eV using magnetic sector mass analyzer (Bremen, Germany). Microanalyses were performed on Elementar-Vario Micro cube Analyzer (Hanau, Germany). Monitoring reactions and determining the homogeneity of the prepared compounds were performed by using thin layer chromatography (TLC) (Sigma-Aldrich). The crystal structures were determined by a Rigaku R-AXIS RAPID diffractometer (Tokyo, Japan) and Bruker X8 Prospector (Madison, WI, USA) and the crystal data collections were made by using Cu-Kα radiation. The data were collected at room temperature. The structure was solved by direct methods and was expanded using Fourier techniques. The non-hydrogen atoms were refined anisotropically. The structure was solved and refined using the Bruker SHELXTL Software Package (Structure solution program-SHELXS-97 and Refinement program-SHELXL-97) \[[@B43-molecules-19-02637]\]. Data were corrected for the absorption effects using the multi-scan method (SADABS). Compounds **10a** and **10b** were prepared according to a literature procedure \[[@B40-molecules-19-02637]\].

3.2. Synthesis
--------------

### 3.2.1. General Procedure for the Preparation of Pyridazin-3-one Derivatives **3a**--**l**

Independent mixtures of **1a**--**l** (5 mmol), *p*-nitrophenylacetic acid **2a** or cyanoacetic acid **2b** (5 mmol), in acetic anhydride (10 mL) were stirred at reflux for 1 h. The mixtures were cooled to room temperature. The formed solids were collected by filtration washed by EtOH and recrystallized from the appropriate solvent.

*6-Benzoyl-4-(4-nitrophenyl)-2-phenylpyridazin-3-(2H)-one* (**3a**)*.* Yellow crystals, yield: (1.65 g, 82%), m.p.: 182--183 °C; IR (KBr): *v*/cm^−1^ 1672, 1655 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ =7.50 (t, *J* = 7.6 Hz, 1H, Ar-H), 7.55--7.60 (m, 4H, Ar-H), 7.68--7.72 (m, 3H, Ar-H), 8.093 (d, *J* = 8.0 Hz, 2H, Ar-H), 8.22 (d, *J* = 8.0 Hz, 2H, Ar-H), 8.29 (s, 1H, pyridazine H5), and 8.37--8.39 (m, 2H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 123.9, 126.6, 128.9, 129.3, 129.4, 129.43, 130.8, 131.1, 133.9, 135.8, 137.9, 140.5, 142.1, 142.9, 148.4, 159.0 and 189.8 ppm (Ar-C and CO); MS (EI): *m/z* (%) 398 (\[M + 1\]^+^, 28.15), 397 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~23~H~15~N~3~O~4~ (M^+^) 397.1057, found 397.1056. Anal. calcd. for C~23~H~15~N~3~O~4~ (397.39): C, 69.52; H, 3.80; N, 10.57. Found: C, 69.43; H, 3.95; N, 10.66. ((\[M + 1\]^+^ has be changed to (\[M + 1\]^+^ and please check)

*6-Benzoyl-2-(4-methoxyphenyl)-4-(4-nitrophenyl)pyridazin-3-(2H)-one* (**3b**). Yellow crystals, yield: (1.79 g, 84%), m.p.: 167--168 °C; IR (KBr): *v*/cm^−1^ 1670, 1645 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 3.83 (s, 3H, OCH~3~), 7.09 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.58 (t, *J* = 8.0 Hz, 2H, Ar-H), 7.63 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.70 (t, *J* = 8.0 Hz, 1H, Ar-H), 8.08 (d, *J* = 8.0 Hz, 2H, Ar-H), 8.22 (d, *J* = 8.8 Hz, 2H, Ar-H), 8.27 (s, 1H, pyridazine H5) and 8.38 ppm (d, *J* = 8.8 Hz, 2H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 55.94 (CH~3~), 114.3, 123.8, 127.7, 128.8, 129.2, 130.7, 131.0, 133.8, 134.9, 135.8, 137.6, 140.5, 142.6, 148.3, 159.0, 159.6 and 189.8 ppm (Ar-C and CO); MS (EI): *m/z* (%) 428 (\[M + 1\]^+^, 34.22), 427 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~24~H~17~N~3~O~5~ (M^+^) 427.1162, found 427.1162.

*6-Benzoyl-2-(4-chlorophenyl)-4-(4-nitrophenyl)pyridazin-3-(2H)-one* (**3c**). Pale orange crystals, yield: (1.9 g, 89%), m.p.: 188--189 °C; IR (KBr): *v*/cm^−1^ 1672, 1639 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.50 (t, *J*= 8.0 Hz, 1H, Ar-H), 7.57 (t, *J* = 8.0 Hz, 2H, Ar-H), 7.65 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.71 (d, *J* = 8.0 Hz, 2H, Ar-H), 8.10 (d, *J* = 8.8 Hz, 2H, Ar-H), 8.21 (d, *J* = 8.8 Hz, 2H, Ar-H), 8.27 (s, 1H, pyridazine H5) and 8.38 ppm (d, *J* = 8.8 Hz, 2H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 123.9, 126.5, 129.0, 129.23, 129.24, 129.3, 130.7, 132.9, 134.4, 137.9, 138.8, 140.3, 141.9, 142.6, 148.3, 158.9 and 188.6 ppm (Ar-C and CO); MS (EI): *m/z* (%) 432 (\[M + 1\]^+^, 35.87), 431 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~23~H~14~^35^Cl N~3~O~4~ (M^+^) 431.0667, found 431.0669.

*6-(4-Fluorobenzoyl)-4-(4-nitrophenyl)-2-phenylpyridazin-3-(2H)-one* (**3d**). Yellow crystals, yield: (1.7 g, 80%), m.p.: 177--178 °C; IR (KBr): *v*/cm^−1^ 1677, 1655 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.39 (t, *J* = 8.4 Hz, 2H, Ar-H), 7.47--7.54 (m, 3H, Ar-H), 7.68 (d, *J* = 8.8 Hz, 2H, Ar-H), 8.15--8.18 (m, 4H, Ar-H), 8.24 (s, 1H, pyridazine H5) and 8.34 ppm (d, *J* = 8.8 Hz, 2H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 115.9, 116.1, 123.8, 126.5, 129.2, 129.3, 130.7, 132.3, 134.03, 134.10, 137.8, 140.3, 142.0, 142.7, 148.3, 158.9, 164.8, 166.4 and 188.2 ppm (Ar-C and CO); MS (EI): *m/z* (%) 416 (\[M + 1\]^+^, 29.69), 415 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~23~H~14~F N~3~O~4~ (M^+^) 415.0962, found 415.0963. Crystal Data, C~23~H~14~F N~3~O~4~, M = 415.38, triclinic, a = 7.751(3) Å, b = 11.283(4) Å, c = 22.132(8) Å, V = 1873(1) Å^3^, α = 90.895(7)°, β = 97.459(7)°, γ = 102.263(8)°, space group: P-1 (\#2), Z = 4, D~calc~ = 1.473 g·cm^−3^, No. of reflection measured 8398, 2 θ ~max~ = 54.8°, R1 = 0.0738 \[[@B38-molecules-19-02637]\].

*2-(4-Chlorophenyl)-6-(4-fluorobenzoyl)-4-(4-nitrophenyl)pyridazin-3-(2H)-one* (**3e**). Yellow crystals, yield: (1.9 g, 84%), m.p.: 214--215 °C; IR (KBr): *v*/cm^−1^ 1675, 1643 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.37--7.40 (m, 2H, Ar-H), 7.60 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.72 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.16--8.18 (m, 4H, Ar-H), 8.23 (s, 1H, pyridazine H5) and 8.33 ppm (d, *J* = 8.4 Hz, 2H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 115.9, 116.1, 123.8, 128.4, 129.3, 130.7, 132.2, 133.7, 134.05, 134.11, 137.9, 140.2, 140.7, 142.9, 148.3, 158.8, 164.8, 166.5 and 188.1 ppm (Ar-C and CO); MS (EI): *m/z* (%) 450 (\[M + 1\]^+^, 24.91), 449 (M^+^, 66.15); HRMS (EI): *m/z* calcd. for C~23~H~13~^35^ClFN~3~O~4~ (M^+^) 449.0573, found 449.0573.

*6-(4-Chlorobenzoyl)-2-(4-chlorophenyl)-4-(4-nitrophenyl)pyridazin-3-(2H)-one* (**3f**).Yellow crystals, yield: (1.8 g, 78%), m.p.: 256--257 °C; IR (KBr): *v*/cm^−1^ 1670, 1648 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.60--7.62 (m, 4H, Ar-H), 7.72 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.07 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.17 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.24 (s, 1H, pyridazine H5) and 8.34 ppm (d, *J* = 8.4 Hz, 2H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 123.9, 128.3, 129.0, 129.25, 129.30, 130.7, 132.9, 133.7, 134.3, 138.0, 138.88, 140.2, 140.7, 142.7, 148.4, 158.9 and 188.5 ppm (Ar-C and CO); MS (EI): *m/z* (%) 466 (\[M + 1\]^+^, 40.45), 465 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~23~H~13~^35^Cl~2~N~3~O~4~ (M^+^) 465.0277, found 465.0277.

*6-(4-Bromobenzoyl)-2-(4-chloro-3-nitrophenyl)-4-(4-nitrophenyl)pyridazin-3-(2H)-one* (**3g)**. Yellow crystals, yield: (2.5 g, 91%), m.p.: 236--237 °C; IR (KBr): *v*/cm^−1^ 1676, 1648 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.80 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.99--8.10 (m, 4H, Ar-H), 8.21 (d, *J* = 7.6 Hz, 2H, Ar-H), 8.29 (s, 1H, pyridazine H5), 8.38 (d, *J* = 7.6 Hz, 2H, Ar-H) and 8.56 ppm (s, 1H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 123.6, 123.8, 125.7, 128.2, 129.3, 130.7, 131.5, 132.0, 132.7, 132.8, 134.7, 138.5, 139.9, 141.1, 143.4, 147.7, 148.8, 158.9 and 188.4 ppm (Ar-C and CO); MS (EI): *m/z* (%) 556 (\[M + 2\]^+^, 87.88), 555 (\[M + 1\]^+^, 41.10), 554 (M^+^, 65.05); HRMS (EI): *m/z* calcd. for C~23~H~12~^79^BrClN~4~O~6~ (M^+^) 553.9623, found 553.9625.

*6-(4-Bromobenzoyl)-2-(4-chloro-3-nitrophenyl)-4-(2-nitrophenyl)pyridazin-3-(2H)-one* (**3h**). Buff crystals, yield: (2.13 g, 77%), m.p.: 218--219 °C; IR (KBr): *v*/cm^−1^ 1679, 1659 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.77--7.85 (m, 4H, Ar-H), 7.94--8.01 (m, 3H, Ar-H), 8.07 (d, *J* = 8.8 Hz, 2H, Ar-H), 8.21 (d, *J* = 8.0 Hz, 1H, Ar-H), 8.26 (s, 1H, pyridazine H5) and 8.45 ppm (d, *J* = 2.0 Hz, 1H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 123.5, 124.9, 125.8, 128.2, 128.4, 128.7, 131.3, 131.8, 132.0, 132.8, 133.0, 133.1, 134.5, 134.9, 140.5, 140.9, 143.5, 147.6, 148.7, 158.3 and 188.4 ppm (Ar-C and CO); MS (EI): *m/z* (%) 556 (\[M + 2\]^+^, 8.85), 555 (\[M + 1\]^+^, 3.44), 554 (M^+^, 5.15); HRMS (EI): *m/z* calcd. for C~23~H~12~^79^BrClN~4~O~6~ (M^+^) 553.9623, found 553.9624.

*6-(4-Bromobenzoyl)-2-(4-chloro-3-nitrophenyl)-3-oxo-2,3-dihydropyridazine-4-carbonitrile* (**3i**). Brown crystals, yield: (1.7 g, 75%), m.p.: above 300 °C; IR (KBr): *v*/cm^−1^ 2220 (CN), 1688, 1654 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.79 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.98 (d, *J* = 8.0 Hz, 2H, Ar-H), 8.01--8.04 (m, 2H, Ar-H), 8.47 (s, 1H, pyridazine H5) and 8.83 ppm (s, 1H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 113.8, 116.1, 123.6, 126.5, 128.6, 131.5, 132.1, 133.0, 133.1, 134.0, 139.5, 139.9, 142.3, 147.5, 156.5 and 187.5 ppm (Ar-C, CN and CO); MS (EI): *m/z* (%) 460 (\[M + 2\]^+^, 22.58), 459 (\[M + 1\]^+^, 7.04), 458 (M^+^, 16.81); HRMS (EI): *m/z* calcd. for C~18~H~8~^79^BrClN~4~O~4~ (M^+^) 457.9411, found 457.9411.

*6-(4-Chlorobenzoyl)-2-(4-chlorophenyl)-3-oxo-2,3-dihydropyridazine-4-carbonitrile* (**3j**). Brown crystals, yield: (1.5 g, 81%), m.p.: above 300 °C; IR (KBr): *v*/cm^−1^ 2218 (CN), 1689, 1662 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.62--7.70 (m, 4H, Ar-H), 7.96 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.00 (d, *J* = 8.4 Hz, 2H, Ar-H) and 8.77 ppm (s, 1H, pyridazine H5); MS (EI): *m/z* (%) 370 (\[M + 1\]^+^, 35.22), 369 (M^+^, 59.38); HRMS (EI): *m/z* calcd. for C~18~H~9~Cl~2~N~3~O~2~ (M^+^) 369.0066, found 369.0063.

*6-Benzoyl-2-(4-methoxyphenyl)-3-oxo-2,3-dihydropyridazine-4-carbonitrile* (**3k**). Brown crystals, yield: (1.4 g, 80%), m.p.: 164--165 °C; IR (KBr): *v*/cm^−1^ 2219 (CN), 1695, 1659 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 3.85 (s, 3H, O*CH~3~*), 7.07 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.35--7.65 (m, 5H, Ar-H), 8.04 (d, *J* = 8.4 Hz, 2H, Ar-H) and 8.75 ppm (s, 1H, pyridazine H5); MS (EI): *m/z* (%) 332 (\[M + 1\]^+^, 16.85), 331 (M^+^, 68.11); HRMS (EI): *m/z* calcd. for C~19~H~13~N~3~O~3~ (M^+^) 331.0951, found 331.0949.

*6-Acety-4-(4-nitrophenyl)l-2-phenylpyridazin-3-(2H)-one* (**3l**). Yellow crystals, yield: (1.5 g, 89%), m.p.: 182--183 °C; IR (KBr): *v*/cm^−1^ 1689, 1672 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 2.51 (s, 3H, CH~3~), 7.51 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.58 (t, *J* = 7.8 Hz, 2H, Ar-H), 7.70 (d, *J* = 7.8 Hz, 2H, Ar-H), 8.11 (s, 1H, pyridazine H5), 8.14 (d, *J* = 8.4 Hz, 2H, Ar-H) and 8.31 ppm (d, *J* = 8.4 Hz, 2H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 25.1 (CH~3~), 123.8, 126.4, 126.8, 129.25, 129.30, 130.7, 137.5, 140.4, 142.0, 142.5, 148.3, 159.1 and 195.1 ppm (Ar-C and CO); MS (EI): *m/z* (%) 336 (\[M + 1\]^+^, 25.08), 335 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~18~H~13~N~3~O~4~ (M^+^) 335.0900, found 335.0901. Crystal Data, C~18~H~13~N~3~O~4~, M = 335.32, monoclinic, a = 25.68(3) Å, b = 3.848(4) Å, c = 32.02(3) Å, V = 3164(5) Å^3^, α = γ = 90°, β = 90.62(2)°, space group: C2/c (\#15), Z = 8, D~calc~ = 1.408 g·cm^−3^, No. of reflection measured 2806, 2 θ ~max~ = 50.1°, R1 = 0.0818 \[[@B39-molecules-19-02637]\].

*(E)-6-(3-(Dimethylamino)acryloyl)-4-(4-nitrophenyl)l-2-phenylpyridazin-3-(2H)-one* (**4**). Mixture of **3l** (1.68 g, 5 mmol), *N*,*N*-dimethylformamide dimethylacetal (DMF-DMA) (0.6 g, 5 mmol) in dioxane (20 mL) were stirred at reflux for 5 h. The separated solid product obtained on standing at room temperature was collected by filtration, washed by EtOH and recrystallized from dioxane to afford the corresponding enamines **4** as orange crystal. Yellow crystals, yield: (1.70 g, 90%), m.p.: 214--215 °C; IR (KBr): *v*/cm^−1^ 1678, 1644 (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 2.84 (s, 3H, CH~3~), 3.15 (s, 3H, CH~3~), 5.88 (d, *J* = 12 Hz, 1H, olefinic CH=CH), 7.49 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.56 (t, *J* = 7.8 Hz, 2H, Ar-H), 7.67 (d, *J* = 7.8 Hz, 2H, Ar-H), 7.81 (d, *J* = 12 Hz, 1H, olefinic CH=CH), 8.13 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.15 (s, 1H, pyridazine H5) and 8.30 ppm (d, *J* = 8.4 Hz, 2H, Ar-H); ^13^C-NMR (DMSO-*d~6~*): δ = 37.6 (CH~3~), 45.1 (CH~3~), 88.6, 123.7, 126.6, 127.9, 128.9, 129.30, 130.6, 137.3, 140.9, 142.3, 144.3, 148.1, 155.1, 159.1 and 180.7 ppm (Ar-C and CO); MS (EI): *m/z* (%) 391 (\[M + 1\]^+^, 19.75), 335 (M^+^, 85.07); HRMS (EI): *m/z* calcd. for C~21~H~18~N~4~O~4~ (M^+^) 390.1322, found 390.1322. Anal. calcd. for C~21~H~18~N~4~O~4~ (390.40): C, 64.61; H, 4.65; N, 14.35. Found C, 64.80; H, 4.77; N, 14.53.

### 3.2.2. General Procedure for the Synthesis of Azolopyrimidines **5**--**7**

Independent mixtures of **4** (0.78 g, 2 mmol) and the appropriate heteroaromatic amine (2 mmol) in pyridine (20 mL) were stirred at reflux for 24 h. The reaction mixtures were cooled to room temperature and poured into ice cold water then acidified with hydrochloric acid (2 N), forming solids that were collected by filtration and washed with water then MeOH and recrystallized from the appropriate solvent.

*4-(4-Nitrophenyl)-2-phenyl-6-(1,2,4-triazolo\[1,5-a\]pyrimidin-7-yl)-(2H)-pyridazin-3-one* (**5**). Pall yellow crystals, yield: (0.7 g, 76%), m.p.: 149--150 °C; IR (KBr): *v*/cm^−1^ 1668 (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.54 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.61 (t, *J* = 8.0 Hz, 2H, Ar-H), 7.79 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.98 (d, *J* = 5.4 Hz, 1H, pyrimidine H6), 8.25 (d, *J* = 8.0 Hz, 2H, Ar-H), 8.38 (d, *J* = 8.0 Hz, 2H, Ar-H), 8.66 (s, 1H, pyridazine H5), 8.80 (s, 1H, triazole H2) and 9.48 ppm (d, *J* = 5.4 Hz, 1H, pyrimidine H5); MS (EI): *m/z* (%) 461 (\[M + 1\]^+^, 30.78), 460 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~26~H~16~N~6~O~3~ (M^+^) 460.1278, found 460.1278.

*4-(4-Nitrophenyl)-2-phenyl-6-(2-phenylpyrazolo\[1,5-a\]pyrimidin-7-yl)-(2H)-pyridazin-3-one* (**6**). Yellow crystals, yield: (0.77 g, 80%), m.p.: 285--286 °C; IR (KBr): *v*/cm^−1^ 1671 (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.43--7.45 (m, 2H, Ar-H), 7.49 (d, *J* = 4.8 Hz, 1H, pyrimidine *H6*), 7.51--7.54 (m, 3H, Ar-H), 7.59 (t, *J* = 7.8 Hz, 2H, Ar-H), 7.80 (d, *J* = 7.8 Hz, 2H, Ar-H), 8.05 (d, *J* = 7.8 Hz, 2H, Ar-H), 8.23 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.40 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.67 (d, *J* = 4.8 Hz, 1H, pyrimidine H5) and 8.96 ppm (s, 1H, pyridazine H5); ^13^C-NMR (DMSO-*d~6~*): δ = 93.9, 107.9, 123.5, 126.1, 126.2, 128.7, 128.8, 129.0, 129.3, 130.1, 130.9, 132.1, 136.1, 138.0, 139.9, 140.2, 141.5, 147.9, 149.9, 150.6, 155.0 and 158.3 ppm (Ar-C and CO); MS (EI): *m/z* (%) 487 (\[M + 1\]^+^, 35.02), 486 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~28~H~18~N~6~O~3~ (M^+^) 486.1434, found 486.1432. Anal. calcd. for C~28~H~18~N~6~O~3~ (486.49): C, 69.13; H, 3.73; N, 17.27. Found C, 69.27; H, 3.65; N, 17.39.

*6-(Benzo\[4,5\]imidazo\[1,2-a\]pyrimidine-4-yl)-4-(4-nitrophenyl)-2-phenyl-(2H)-pyridazin-3-one* (**7**). Yellow crystals, yield: (0.6 g, 73%), m.p.: above 300 °C; IR (KBr): *v*/cm^−1^ 1669 (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.45 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.54 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.57--762 (m, 3H, Ar-H), 7.74 (d, *J* = 5.4 Hz, 1H, pyrimidine H6), 7.80 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.88 (d, *J* = 7.8 Hz, 1H, Ar-H), 8.24 (d, *J* = 9.0 Hz, 2H, Ar-H), 8.28 (d, *J* = 7.8 Hz, 1H, Ar-H), 8.34 (d, *J* = 9.0 Hz, 2H, Ar-H), 8.69 (s, 1H, pyridazine H5) and 9.48 ppm (d, *J* = 5.4 Hz, 1H, pyrimidine H5); ^13^C-NMR (DMSO-*d~6~*): δ = 102.9, 112.9, 119.5, 119.9, 122.5, 123.7, 126.4, 126.7, 127.8, 129.0, 129.2, 130.7, 136.6, 138.3, 140.7, 142.4, 142.7, 145.2, 148.7, 150.2, 157.0 and 159.1 ppm (Ar-C and CO); MS (EI): *m/z* (%) 412 (\[M + 1\]^+^, 26.11), 411 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~21~H~13~N~7~O~3~ (M^+^) 411.1074, found 411.1074.

### 3.2.3. General Procedure for the Preparation of Compounds **16**--**20**

Independent mixtures of **8a** (1.03 g, 2.5 mmol), cyanoacetylindoles **11**,**12**, cyanoacetamides **13**--**15** (2.5 mmol), and ammonium acetate (2 g) in acetic acid (20 mL) were stirred at reflux for 1--2 h. (progress of the reactions monitored by using TLC with 1:1 ethyl acetate/petroleum ether as eluent). The mixtures were cooled to room temperature. The formed solids were collected by filtration and crystallized from the indicated solvents to give **16**--**20** as pure products.

*\[2-Amino-6-(4-bromophenyl)-5-(4-chloro-3-nitrophenylazo)pyridin-3-yl\](1-methyl-1H-indol-3-yl)-methanone* (**16**). Recrystallized from EtOH/DMF mixture (1:1) as pale brown crystals, yield: (1.10 g, 75%), m.p.: 273--274 °C; IR (KBr): *v*/cm^−1^ 3329, 3279 (NH~2~), 1635( (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 3.89 (s, 3H, CH~3~), 7.32 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.37 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.62 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.74 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.82 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.87 (s, 2H, NH~2~), 7.88--7.93 (m, 2H, Ar-H), 8.13 (s, 1H, indole H2), 8.24 (d, *J* = 8.0 Hz, 1H, Ar-H), 8.30 (s, 1H, Ar-H) and 8.39 ppm (s, 1H, pyridine H4); ^13^C-NMR (DMSO-*d~6~* at 80 °C): δ = 33.7 (CH~3~), 111.2 (pyridine C3), 115.4, 117.3, 119.5, 122.1, 122.8, 123.6, 123.9, 126.2, 127.0, 127.2, 127.5, 131.0, 133.2, 133.4, 137.1, 138.2, 139.3, 145.0, 148.8, 152.0, 159.9, 160.2 and 189.0 ppm (Ar-C and CO); MS (EI): *m/z* (%) 590 (\[M + 2\]^+^, 37.92), 589 (\[M + 1\]^+^, 36.11), 588 (M^+^, 26.44); HRMS (EI): *m/z* Calcd. for C~27~H~18~^79^Br^35^ClN~6~O~3~ (M^+^) 588.0306, found 588.0306. Anal. calcd. for C~27~H~18~BrClN~6~O~3~ (589.84): C, 54.98; H, 3.08; N, 14.25. Found C, 54.83; H, 3.17; N, 14.11.

*\[2-Amino-6-(4-bromophenyl)-5-(4-chloro-3-nitrophenylazo)pyridin-3-yl\](2-methyl-1H-indol-3-yl)- methanone* (**17**). Recrystallized from EtOH/DMF mixture (1:1) as pale brown crystals, yield: (1.16 g, 79%), m.p.: 292--293 °C; IR (KBr): *v*/cm^−1^ 3345, 3267, 3168 (NH~2~ and NH), 1631( (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 2.48 (s, 3H, CH~3~), 7.06 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.15 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.42 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.53 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.73 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.80--7.88 (m, 4H, Ar-H),7.94 (s, 2H, NH~2~), 8.19 (d, *J* = 2.4 Hz, 1H, Ar-H), 8.26 (s, 1H, pyridine H4) and 12.07 ppm (s, 1H, NH); ^13^C-NMR (DMSO-*d~6~*): δ = 14.4 (CH~3~), 111.5 (pyridine C3), 112.7, 117.1, 119.4, 119.9, 121.3, 122.1, 123.2, 125.7, 126.3, 127.1, 127.8, 130.6, 132.7, 133.2, 135.0, 136.1, 136.4, 144.4, 148.0, 151.1, 159.5, 160.0 and 190.2 ppm (Ar-C and CO); MS (EI): *m/z* (%) 590 (\[M + 2\]^+^, 28.79), 589 (\[M + 1\]^+^, 26.98), 588 (M^+^, 21.03); HRMS (EI): *m/z* Calcd. for C~27~H~18~^79^BrClN~6~O~3~ (M^+^) 588.0306, found 588.0307.

*2-Amino-6-(4-bromophenyl)-N-(4-chloro-3-nitrophenyl)-5-(4-chloro-3-nitrophenylazo)nicotin-amide* (**18**). Recrystallized from dioxane as orange crystals, yield: (1.27 g, 81%), m.p.: 299--300 °C; IR (KBr): *v*/cm^−1^ 3371, 3266, 3170 (NH~2~ and NH), 1658 (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.69 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.74--7.76 (m, 3H, Ar-H), 7.91--7.99 (m, 3H, Ar-H), 8.04 (s, 2H, NH~2~), 8.28 (d, *J* = 2.4 Hz, 1H, Ar-H), 8.50 (d, *J* = 2.4 Hz, 1H, Ar-H), 8.57 (s, 1H, pyridine H4) and 11.00 ppm (s, 1H, NH); ^13^C-NMR (DMSO-*d~6~*): δ = 110.2 (pyridine C3), 117.0, 119.2, 119.3, 123.3, 125.4, 125.6, 126.0, 126.7, 130.5, 131.9, 133.0, 133.1, 135.9, 136.2, 138.7, 147.0, 148.0, 151.1, 159.9, 160.4 and 166.1 ppm (Ar-C and CO); MS (EI): *m/z* (%) 631 (\[M + 2\]^+^, 66.14), 630 (\[M + 1\]^+^, 100), 629 (M^+^, 50.07); HRMS (EI): *m/z* Calcd. for C~24~H~14~^79^BrCl~2~N~7~O~5~ (M^+^) 628.9611, found 628.9611. Crystal Data, C~52~H~36~Br~2~Cl~4~N~14~O~12~, M = 1350.57, triclinic, a = 8.0796(5) Å, b = 11.0560(7) Å, c = 16.1457(11) Å, V = 1336.71(15) Å^3^, α = 72.539(5)°, β = 76.338(5)°, γ = 86.790(6)°, space group: P-1, Z = 1, D~calc~ = 1.678 g·cm^−3^, No. of reflection measured 6079, 2 θ ~max~ = 27.44°, R1 = 0.0386 \[[@B42-molecules-19-02637]\].

*N-(5-Acetyl-2-phenyl-2H-1,2,3-triazol-4-yl)-2-amino-6-(4-bromophenyl)-5-(4-chloro-3-nitrophenyl)-nicotinamide* (**19**). Recrystallized from dioxane as deep orange crystals, yield: (1.19 g. 72%), m.p.: above 300 °C; IR (KBr): *v*/cm^−1^ 3382, 3351, 3166 (NH~2~ and NH), 1689, 1659 ( (2CO); ^1^H-NMR (DMSO-*d~6~*): δ = 2.66 (s, 3H, CH~3~), 7.54 (t, *J* = 7.6 Hz, 1H, Ar-H), 7.65 (t, *J* = 7.6 Hz, 2H, Ar-H), 7.72 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.79--7.82 (m, 2H, Ar-H), 7.99 (s, 2H, NH~2~), 8.07--8.10 (m, 4H, Ar-H), 9.30 (s, 1H, Ar-H), 8.74 (s, 1H, pyridine H4) and 11.21 ppm (s, 1H, NH); MS (EI): *m/z* (%) 661 (\[M + 2\]^+^, 77.95), 660 (\[M + 1\]^+^, 100), 659 (M^+^, 56.01); HRMS (EI): *m/z* Calcd. for C~28~H~19~^79^BrClN~9~O~4~ (M^+^) 659.0426, found 659.0428.

*6-(4-Bromobenzoyl)-2-(4-chloro-3-nitrophenyl)-3-imino-2,3-dihydropyridazine-4-carboxylic acid (3-cyano-4-phenylthiophen-2-yl)amide* (**20a**). Recrystallized from EtOH/DMF mixture (1:3) as pale brown crystals, yield: (1.27 g, 77%), m.p.: 270--271 °C; IR (KBr): *v*/cm^−1^ 3426, 3346 (2 NH), 2216 (CN), 1678, 1659 (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.16 (s, 1H, thiophene H5), 7.37 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.47 (t, *J* = 8.0 Hz, 2H, Ar-H), 7.63 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.75 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.95 (d, *J* = 8.8 Hz, 2H, Ar-H), 8.16--8.23 (m, 2H, Ar-H), 8.73 (d, *J* = 2.0 Hz, 1H, Ar-H), 8.79 (s, 1H, pyridazine H5), 9.85 (s, 1H, imine NH) and 13.32 ppm (s, 1H, amide NH); ^13^C-NMR (DMSO-*d~6~*): δ = 94.4 (thiophene C-3), 114.9, 117.8, 125.3, 127.0, 127.7, 128.40, 128.42, 128.8, 130.9, 131.2, 131.7, 132.6, 132.8, 133.4, 134.51, 134.54, 136.8, 138.8, 146.3, 148.2, 155.0, 161.0, 163.4 and 187.4 ppm (Ar-C, CN and CO); MS (EI): *m/z* (%) 660 (\[M + 2\]^+^, 7.95), 659 (\[M + 1\]^+^, 2.73), 658 (M^+^, 6.55); HRMS (EI): *m/z* Calcd. for C~29~H~16~^79^BrClN6O~4~S (M^+^) 657.9820, found 657.9820.

6*-(4-Bromobenzoyl)-2-(4-chloro-3-nitrophenyl)-3-imino-2,3-dihydropyridazine-4-carboxylic acid \[4-(4-chlorophenyl)-3-cyanothiophen-2-yl\]amide* (**20b**). Recrystallized from EtOH/DMF mixture (1:3) as yellowish brown crystals, yield: (1.26 g, 73%), m.p.: 288--289 °C; IR (KBr): *v*/cm^−1^ 3401, 3349 (2 NH), 2214 (CN), 1673, 1654 (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.16 (s, 1H, thiophene H5), 7.53 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.65 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.76 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.95 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.17--8.19 (m, 2H, Ar-H), 8.71 (d, *J* = 2.0 Hz, 1H, Ar-H), 8.78 (s, 1H, pyridazine H5), 9.84 (s, 1H, imine NH) and 13.25 ppm (s, 1H, amide NH); ^13^C-NMR (DMSO-*d~6~*): δ = 94.1 (thiophene C-3), 115.5, 117.6, 125.2, 128.4, 128.7, 128.8, 131.0, 131.2, 131.7, 132.4, 132.6, 132.8, 133.36, 133.39, 134.5, 135.4, 138.8, 146.3, 148.1, 155.0, 161.1, 163.7 and 187.5 ppm (Ar-C, CN and CO); MS (EI): *m/z* (%) 694 (\[M + 2\]^+^, 11.84), 693 (\[M + 1\]^+^, 5.12), 692 (M^+^, 8.92); HRMS (EI): *m/z* Calcd. for C~29~H~15~^79^BrCl~2~N6O~4~S (M^+^) 691.9430, found 691.9432.

### 3.2.4. General Procedure for the Preparation of Naphthyridine Derivatives **24a**,**b**

Independent solutions of cyanoacetic acid (0.425 g, 5 mmol) in Ac~2~O (10 mL) was heated at 100 °C for 5 min. then compounds **10a**,**b** (5 mmol) were added and the reaction mixtures were heated for further 30 min. at 100 °C. Then the reaction mixtures were allowed to cool to room temperature and the formed crystalline solids were separated by filtration, washed with ethanol and recrystallized from the proper solvent.

*7-(4-Bromophenyl)-6-(4-chloro-3-nitrophenylazo)-2-oxo-4-phenyl-1,2-dihydro\[1,8\]naphthyridine-3-carbonitrile* (**24a**).Recrystallized from EtOH/dioxane mixture (1:1) as pale brown crystals, yield: (2.54 g, 80%), m.p.: above 300 °C; IR (KBr): *v*/cm^−1^ 3397 (NH), 2220 (CN), 1673 (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.51--7.53 (m, 2H, Ar-H), 7.62--7.63 (m, 3H, Ar-H), 7.71 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.77 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.80--7.89 (m, 3H, 2 Ar-H and pyridine H4), 8.18 (d, *J* = 2.4 Hz, 1H, Ar-H) and 13.33 ppm (s, 1H, NH); ^13^C-NMR (DMSO-*d~6~*): δ = 107.3, 113.5, 117.7, 120.0, 122.5, 123.6, 126.6, 127.0, 129.3, 129.5, 130.1, 131.1, 133.2, 133.6, 134.5, 137.5, 138.7, 145.6, 148.5, 151.4, 157.9, 158.0 and 160.7 ppm (Ar-C, CN and CO); MS (EI): *m/z* (%) 586 (\[M + 2\]^+^, 61.03), 585 (\[M + 1\]^+^, 84.11), 584 (M^+^, 47.05); HRMS (EI): *m/z* calcd. for C~27~H~14~^79^Br^35^ClN~6~O~3~ (M^+^) 583.9993, found 583.9991. Anal. calcd. for C~27~H~14~BrClN~6~O~3~ (585.81): C, 55.36; H, 2.41; N, 14.35. Found C, 55.24; H, 2.49; N, 14.27.

*\[7-(4-Chlorophenyl)-6-(4-chloro-3-nitrophenylazo)-2-oxo-4-phenyl-1,2-dihydro\[1,8\]naphthyridine-3-carbonitrile* (**24b**). Recrystallized from EtOH/dioxane mixture (1:1) as pale brown crystals, yield: (2.21 g, 82%), m.p.: above 300 °C; IR (KBr): *v*/cm^−1^ 3372 (NH), 2228 (CN), 1672 (CO); ^1^H-NMR (DMSO-*d~6~*): δ = 7.56--7.61 (m, 4H, Ar-H), 7.65--7.68 (m, 3H, Ar-H), 7.81--7.85 (m, 3H, Ar-H), 7.87--7.91 (m, 2H, 1 Ar-H and pyridine H4), 8.23 (d, *J* = 2.4 Hz, 1H, Ar-H) and 13.45 ppm (s, 1H, NH); ^13^C-NMR (DMSO-*d~6~*): δ = 108.2, 113.6, 114.8, 120.2, 123.9, 126.7, 127.7, 128.1, 128.8, 129.1, 130.6, 132.3, 132.9, 133.1, 134.7, 135.4, 140.6, 148.0, 150.3, 151.3, 159.3, 159.45 and 159.52 ppm (Ar-C, CN and CO); MS (EI): *m/z* (%) 541 (\[M + 1\]^+^, 88.31), 540 (M^+^, 100); HRMS (EI): *m/z* calcd. for C~27~H~14~^35^Cl~2~N~6~O~3~ (M^+^) 540.0498, found 540.0495.

4. Conclusions
==============

The results of the study described above have led to the development of a simple approach for the synthesis of a novel class of pyridazin-3-one and 2-aminopyridine derivatives. Furthermore, the observations made during this work showed that these compounds are versatile precursors for the synthesis of some very important fused azines like azolo\[1,5-*a*\]pyrimidines and 1,8-naphthyridines, for which we expect a wide range of biological activity.
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